The thyromimetic T-0681 protects from atherosclerosis

Journal of Lipid Research

Volumn 50, Issue 5, 2009, Pages 938-944

  Tancevski, Ivan ^a   Wehinger, Andreas ^c   Demetz, Egon ^a   Hoefer, Julia ^a   Eller, Philipp ^a   Huber, Eva ^a   Stanzl, Ursula ^a   Duwensee, Kristina ^a   Auer, Kristina ^a   Schgoer, Wilfried ^a   Kuhn, Volker ^b   Fievet, Catherine ^d   Stellaard, Frans ^e   Rudling, Mats ^f   Foeger, Bernhard ^c   Patsch, Josef R ^a   Ritsch, Andreas ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d INSTITUT PASTEUR DE LILLE   (France)

^e UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^f KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Liver selective thyromimetic; Low density lipoprotein receptor; Potential side effects; Scavenger receptor class B, type I

Indexed keywords

APOLIPOPROTEIN B; CHOLESTEROL ESTER TRANSFER PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; KAT 681; LOW DENSITY LIPOPROTEIN RECEPTOR; PLACEBO; SCAVENGER RECEPTOR BI; T 0681; THYROMIMETIC AGENT; UNCLASSIFIED DRUG; CD36 ANTIGEN; DIPHENYL ETHER DERIVATIVE; HYPOCHOLESTEROLEMIC AGENT; MALONIC ACID DERIVATIVE; N (4 (3 ((4 FLUOROPHENYL)HYDROXYMETHYL) 4 HYDROXYPHENOXY) 3,5 DIMETHYLPHENYL) MALONAMIC ACID SODIUM; N-(4-(3-((4-FLUOROPHENYL)HYDROXYMETHYL)-4-HYDROXYPHENOXY)-3,5-DIMETHYLPHENYL) MALONAMIC ACID SODIUM;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HYPERLIPIDEMIA; LIPID DIET; LIPID METABOLISM; LIPOPROTEIN METABOLISM; MALE; NONHUMAN; PRIORITY JOURNAL; RABBIT; RECEPTOR UPREGULATION; TRIACYLGLYCEROL BLOOD LEVEL; ANIMAL; AORTA; CELL LINE; CHOLESTEROL INTAKE; DIET; DISEASE MODEL; HISTOLOGY; LIVER; METABOLISM; PATHOLOGY;

ANIMALS; ANTICHOLESTEREMIC AGENTS; ANTIGENS, CD36; AORTA; ATHEROSCLEROSIS; CELL LINE; CHOLESTEROL, DIETARY; DIET; DISEASE MODELS, ANIMAL; HUMANS; HYPERLIPIDEMIAS; LIPID METABOLISM; LIVER; MALE; MALONATES; PHENYL ETHERS; RABBITS;

EID: 67649713432     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M800553-JLR200     Document Type: Article

References (32)

1. Duntas, L. H. 2002. Thyroid disease and lipids. Thyroid. 12: 287-293.
2. Staels, B., A. Van Tol, L. Chan, H. Will, G. Verhoeven, and J. Auwerx. 1990. Alterations in thyroid status modulate apolipoprotein, hepatic triglyceride lipase, and low density lipoprotein receptor in rats. Endocrinology. 127: 1144-1152.
3. Bakker, O., F. Hudig, S. Meijssen, and W. M. Wiersinga. 1998. Effects of triiodothyronine and amiodarone on the promoter of the human LDL receptor gene. Biochem. Biophys. Res. Commun. 249: 517-521.
4. Scarabottolo, L., E. Trezzi, P. Roma, and A. L. Catapano. 1986. Experimental hypothyroidism modulates the expression of the low density lipoprotein receptor by the liver. Atherosclerosis. 59: 329-333.
5. Packard, C. J., J. Shepherd, G. M. Lindsay, A. Gaw, and M. R. Taskinen. 1993. Thyroid replacement therapy and its influence on postheparin plasma lipases and apolipoprotein-B metabolism in hypothyroidism. J. Clin. Endocrinol. Metab. 76: 1209-1216.
6. Johansson, L., M. Rudling, T. S. Scanlan, T. Lundasen, P. Webb, J. Baxter, B. Angelin, and P. Parini. 2005. Selective thyroid receptor modulation by GC-1 reduces serum lipids and stimulates steps of reverse cholesterol transport in euthyroid mice. Proc. Natl. Acad. Sci. USA. 102: 10297-10302.
7. Morkin, E., P. Ladenson, S. Goldman, and C. Adamson. 2004. Thyroid hormone analogs for treatment of hypercholesterolemia and heart failure: past, present and future prospects. J. Mol. Cell. Cardiol. 37: 1137-1146.
8. Gullberg, H., M. Rudling, C. Salto, D. Forrest, B. Angelin, and B. Vennstrom. 2002. Requirement for thyroid hormone receptor beta in T3 regulation of cholesterol metabolism in mice. Mol. Endocrinol. 16: 1767-1777.
9. Grover, G. J., K. Mellstrom, L. Ye, J. Malm, Y. L. Li, L. G. Bladh, P. G. Sleph, M. A. Smith, R. George, B. Vennstrom, et al. 2003. Selective thyroid hormone receptor-beta activation: a strategy for reduction of weight, cholesterol, and lipoprotein (a) with reduced cardiovascular liability. Proc. Natl. Acad. Sci. USA. 100: 10067-10072.
10. Erion, M. D., E. E. Cable, B. R. Ito, H. Jiang, J. M. Fujitaki, P. D. Finn, B. H. Zhang, J. Hou, S. H. Boyer, P. D. van Poelje, et al. 2007. Targeting thyroid hormone receptor-beta agonists to the liver reduces cholesterol and triglycerides and improves the therapeutic index. Proc. Natl. Acad. Sci. USA. 104: 15490-15495.
11. Berkenstam, A., J. Kristensen, K. Mellstrom, B. Carlsson, J. Malm, S. Rehnmark, N. Garg, C. M. Andersson, M. Rudling, F. Sjoberg, et al. 2008. The thyroid hormone mimetic compound KB2115 lowers plasma LDL cholesterol and stimulates bile acid synthesis without cardiac effects in humans. Proc. Natl. Acad. Sci. USA. 105: 663-667.
12. Hayashi, M., H. Ohnota, T. Tamura, J. Kuroda, N. Shibata, M. Akahane, H. Moriwaki, N. Machida, and K. Mitsumori. 2004. Inhibitory effects of KAT-681, a liver-selective thyromimetic, on development of hepatocellular proliferative lesions in rats induced by 2-acetylaminofluorene and partial hepatectomy after diethylnitrosamine initiation. Arch. Toxicol. 78: 460-466.
13. Ritsch, A., I. Tancevski, W. Schgoer, C. Pfeifhofer, R. Gander, P. Eller, B. Foeger, U. Stanzl, and J. R. Patsch. 2004. Molecular characterization of rabbit scavenger receptor class B types I and II: portal to central vein gradient of expression in the liver. J. Lipid Res. 45: 214-222.
14. Ritsch, A., and J. R. Patsch. 2003. Cholesteryl ester transfer protein: gathering momentum as a genetic marker and as drug target. Curr. Opin. Lipidol. 14: 173-179.
15. Tancevski, I., S. Frank, P. Massoner, U. Stanzl, W. Schgoer, A. Wehinger, C. Fievet, P. Eller, J. R. Patsch, and A. Ritsch. 2005. Increased plasma levels of LDL cholesterol in rabbits after adenoviral overexpression of human scavenger receptor class B type I. J. Mol. Med. 83: 927-932.
16. Singaraja, R. R., C. Fievet, G. Castro, E. R. James, N. Hennuyer, S. M. Clee, N. Bissada, J. C. Choy, J. C. Fruchart, B. M. McManus, et al. 2002. Increased ABCA1 activity protects against atherosclerosis. J. Clin. Invest. 110: 35-42.
17. Miesenbock, G., B. Holzl, B. Foger, E. Brandstatter, B. Paulweber, F. Sandhofer, and J. R. Patsch. 1993. Heterozygous lipoprotein lipase deficiency due to a missense mutation as the cause of impaired triglyceride tolerance with multiple lipoprotein abnormalities. J. Clin. Invest. 91: 448-455.
18. Jones, C., R. E. Hammer, W. P. Li, J. C. Cohen, H. H. Hobbs, and J. Herz. 2003. Normal sorting but defective endocytosis of the low density lipoprotein receptor in mice with autosomal recessive hypercholesterolemia. J. Biol. Chem. 278: 29024-29030.
19. Tancevski, I., A. Wehinger, W. Schgoer, P. Eller, S. Cuzzocrea, B. Foeger, J. R. Patsch, and A. Ritsch. 2006. Aspirin regulates expression and function of scavenger receptor-BI in macrophages: studies in primary human macrophages and in mice. FASEB J. 20: 1328-1335.
20. Zhao, S. P., and S. Z. Dong. 2008. Effect of tumor necrosis factor alpha on cholesterol efflux in adipocytes. Clin. Chim. Acta. 389: 67-71.
21. Rozen, S., and H. J. Skaletsky. 2000. Primer3 on the WWW for general users and for biologist programmers. In Bioinformatics Methods and Protocols: Methods in Molecular Biology. S. Krawetz and S. Misener, editors. Humana Press, Totowa, NJ. 365-386.
22. Alexandersen, P., C. Hassager, and C. Christiansen. 2001. Influence of female and male sex steroids on body composition in the rabbit model. Climacteric. 4: 219-227.
23. Schaefer, A., G. P. Meyer, B. Brand, D. Hilfiker-Kleiner, H. Drexler, and G. Klein. 2005. Effects of anesthesia on diastolic function in mice assessed by echocardiography. Echocardiography. 22: 665-670.
24. Tangirala, R. K., E. M. Rubin, and W. Palinski. 1995. Quantitation of atherosclerosis in murine models: correlation between lesions in the aortic origin and in the entire aorta, and differences in the extent of lesions between sexes in LDL receptor-deficient and apolipoprotein E-deficient mice. J. Lipid Res. 36: 2320-2328.
25. Wang, N., W. Weng, J. L. Breslow, and A. R. Tall. 1996. Scavenger receptor BI (SR-BI) is up-regulated in adrenal gland in apolipoprotein A-I and hepatic lipase knock-out mice as a response to depletion of cholesterol stores. In vivo evidence that SR-BI is a functional high density lipoprotein receptor under feedback control. J. Biol. Chem. 271: 21001-21004.
26. Han, J., A. C. Nicholson, X. Zhou, J. Feng, A. M. Gotto, Jr., and D. P. Hajjar. 2001. Oxidized low density lipoprotein decreases macrophage expression of scavenger receptor B-I. J. Biol. Chem. 276: 16567-16572.
27. Niemeier, A., W. J. Kovacs, W. Strobl, and H. Stangl. 2008. Atherogenic diet leads to posttranslational down-regulation of murine hepatocyte SR-BI expression. Atherosclerosis. 202: 169-175.
28. Tancevski, I., A. Wehinger, E. Demetz, P. Eller, K. Duwensee, J. Huber, K. Hochegger, W. Schgoer, C. Fievet, F. Stellaard, et al. 2008. Reduced plasma high-density lipoprotein cholesterol in hyperthyroid mice coincides with decreased hepatic adenosine 5′-triphosphate-binding cassette transporter 1 expression. Endocrinology. 149: 3708-3712.
29. Tanigawa, H., J. T. Billheimer, J. Tohyama, Y. Zhang, G. Rothblat, and D. J. Rader. 2007. Expression of cholesteryl ester transfer protein in mice promotes macrophage reverse cholesterol transport. Circulation. 116: 1267-1273.
30. Mason, R. L., H. M. Hunt, and L. Hurxthal. 1930. Blood cholesterol values in hyperthyroidism and hypothyroidism. N. Engl. J. Med. 203: 1273-1278.
31. The Coronary Drug Project Group. 1972. The coronary drug project. Findings leading to further modifications of its protocol with respect to dextrothyroxine. The coronary drug project research group. JAMA. 220: 996-1008.
32. Moreno, M., P. de Lange, A. Lombardi, E. Silvestri, A. Lanni, and F. Goglia. 2008. Metabolic effects of thyroid hormone derivatives. Thyroid. 18: 239-253.